Compounded tirzepatide with B6 explained

A pen of Zepbound and a vial labelled tirzepatide with vitamin B6 can share the same active molecule and still not be the same medicine. The approved Zepbound label lists^[1] a fixed set of inactive ingredients: sodium chloride, a sodium phosphate buffer salt and water for injection, with benzyl alcohol, glycerin and phenol in the multi-dose presentations. Vitamin B6 is not on that list. A compounded preparation that adds a vitamin is a different product, made under different rules, and the trial evidence behind branded tirzepatide does not automatically carry across to it.

What compounding means in plain terms

Compounding is the practice of preparing a medicine to order in a pharmacy rather than dispensing a mass-produced licensed pack. US law sets out two routes. Under section 503A^[2], a licensed pharmacist or physician may compound a drug "for an identified individual patient based on the receipt of a valid prescription order". Under section 503B^[3], a registered outsourcing facility may prepare batches, and the statute says such a facility "may or may not obtain prescriptions for identified individual patients".

Both routes work by exemption. The law switches off the sections that would otherwise require a new drug application before marketing^[2]. A compounded tirzepatide preparation has therefore never been through approval at all. No regulator has checked its strength, its shelf stability, or what happens when something else goes into the vial. An opinion from the endocrine and metabolism network of the American College of Clinical Pharmacy^[4] states the consequence plainly: compounded incretins do not undergo approval by the Food and Drug Administration.

Why compounded tirzepatide exists, and why it stayed

The market grew when branded supply could not meet demand and the out-of-pocket price put the licensed product beyond many people. It did not fold when supply recovered. A secret-shopper study published in JAMA Health Forum in 2026^[5] surveyed 75 weight-loss clinics and medical spas in two US states after the semaglutide and tirzepatide shortages had ended. It found 42 of them, 56.0 percent, still offering compounded GLP-1 products combined with B vitamins. Of the supplying facilities the investigators traced, 4 of the 21 they could assess were not licensed to perform sterile compounding.

Combination preparations are not a fringe practice. They were the majority of what was on offer in that sample, and the licensing status behind them varied. Legal status for the licensed product differs by country, and we track it for the United States, the United Kingdom and Germany.

The vitamin B6 question, answered honestly

Vitamin B6, also called pyridoxine, is one of the additives that turns up in these preparations. The safety issue with B6 is total intake sustained over time. Medsafe, New Zealand's medicines safety authority, published a prescriber update^[6] stating that long-term use of high doses of vitamin B6 is associated with severe peripheral neuropathy, and that cases have also been reported in patients taking lower doses for a prolonged period. Symptoms it lists include burning or tingling sensations, weakness and reduced reflexes. Recommended daily intake, by comparison, sits between 0.5 and 1.7 mg.

That is the limit of what can fairly be said. The regulator warning is about vitamin B6 as a substance. Market surveys show B vitamins being added to compounded tirzepatide and other incretin preparations. Turning those two facts into a measured risk for one named product would need evidence that is not public. What is fair to note is that someone injecting a combination preparation usually cannot verify the milligram content, and may be taking B6 in a multivitamin as well.

What testing has found inside compounded vials

Analytical work published in Expert Opinion on Drug Safety in 2026^[7] tested samples of compounded tirzepatide combined with vitamin B12 bought from various US sources. The authors identified a widespread, previously unidentified impurity formed by a reaction between tirzepatide and certain B12 analogs. Their own framing stays careful: the clinical effects are unknown. Adding a second active ingredient to a peptide is a chemical event, and it can produce material that was in neither starting component.

The same pattern recurs across the testing literature on non-branded injectables. We have covered composition and labelling failures in retatrutide samples and injection errors with grey-market semaglutide. Contents that do not match the label is the repeating finding, and it runs both ways: under-strength, over-strength, or carrying something unlisted. Status for retatrutide and for semaglutide in Denmark and the United States sits on the country pages.

What the withdrawal trial actually measured

Response to tirzepatide varies between people, and the phase 3 programme reports ranges rather than one number. SURMOUNT-4^[8], published in JAMA in 2024, is the withdrawal trial. Participants took the maximum tolerated dose, 10 or 15 mg weekly, through a 36-week open-label lead-in and lost a mean 20.9 percent of body weight. A total of 670 were then randomised to continue tirzepatide or switch to placebo for 52 more weeks. Mean weight change from week 36 to week 88 was minus 5.5 percent on continued treatment and plus 14.0 percent on placebo.

What that trial did not do was restart anyone on a different preparation and measure the outcome. No published randomised trial has compared stopping the licensed product and re-initiating on a compounded version. Readers wanting the broader stopping-and-regain picture can read what happens after stopping semaglutide, and the general considerations in switching between peptides.

What we do not know

Several things stay genuinely open. Nobody has published a head-to-head trial of a compounded preparation against licensed tirzepatide, so there is no measured comparison of what either produces. The clinical meaning of the B12-related impurity is unknown, as the researchers who found it say themselves. The B6 content across marketed combination preparations is not systematically reported anywhere we could find. And the market surveys describe what businesses advertise, not what happens to the people using the products.

If a preparation is not doing what you expected

Weight moving the wrong way in the first weeks, a plateau that will not shift over months, or bloating that does not settle are all worth describing to the prescribing clinician, with the product in hand. A clinician can consider whether the preparation is what it claims to be, whether something else is contributing, and whether a licensed route to tirzepatide is reachable where you live. Self-adjusting an unapproved injectable, or layering another agent on top, adds variables to a picture that already has too many. PeptideMethods does not give individual medical advice and does not recommend any preparation or supplier.